Fig. 2.
Relationships between human genetic variants and levonorgestrel AUC0-8h among women in A5375. Left panel: relationship between levonorgestrel dose and levonorgestrel AUC0-8h among CYP2B6 normal and intermediate metabolizers in women with HIV on efavirenz, and who received a single 1.5 mg or 3 mg oral dose of levonorgestrel. Panel second from left: relationship between levonorgestrel dose and levonorgestrel AUC0-8h among CYP2B6 poor metabolizers in women with HIV on efavirenz, and who received a single 1.5 mg or 3 mg oral dose of levonorgestrel. Panel second from right: relationship between NAT2 genotype and levonorgestrel AUC0-8h among women with tuberculosis on isoniazid and rifampin, and who received a single 3 mg oral dose of levonorgestrel. Right panel: levonorgestrel AUC0-8h in women with HIV on dolutegravir, and who received a single 1.5 mg oral dose of levonorgestrel. Error bars indicate the median and interquartile range. Clear and gray shaded markers represent 1.5 mg or 3 mg doses of levonorgestrel, respectively. The markers are unadjusted for BMI or age. The horizontal dashed line indicates a median AUC0-8h in the dolutegravir control group. P values from multivariable linear regression are shown. DTG, dolutegravir, EFV, efavirenz, INH, isoniazid, Inter, intermediate, inter, intermediate, LNG, levonorgestrel, RIF, rifampin.